Exploratory Study on Companion/Complimentary Diagnosis Platforms for Immune Checkpoint Inhibitor Treatment of Urothelial Cancer Based on Plasma Cell-free DNA
Not Applicable
- Conditions
- rothelial cancer
- Registration Number
- JPRN-UMIN000041413
- Lead Sponsor
- Kyoto University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Those who did not give a consent for the secondary use of the sample. Those who opted out the refusal to participate this research.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concordance index of tumor somatic mutation profile based on cfDNA sequence for gene mutation profile, TMB, gene expression profile, immunohistological findings based on tumor tissue.
- Secondary Outcome Measures
Name Time Method Predictive values of tumor somatic mutation profile based on cfDNA sequence for patient prognosis and treatment response.